When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
- Home |
- ‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
- June 5, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
